---
document_datetime: 2025-11-23 08:01:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ritemvia.html
document_name: ritemvia.html
version: success
processing_time: 0.107677
conversion_datetime: 2025-12-27 22:12:30.741737
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ritemvia

[RSS](/en/individual-human-medicine.xml/65709)

##### Withdrawn

This medicine's authorisation has been withdrawn

rituximab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ritemvia](#news-on)
- [Related content](#related-content-506)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 June 2021, the European Commission withdrew the marketing authorisation for Ritemvia (rituximab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Celltrion Healthcare Hungary Kft., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ritemvia was granted marketing authorisation in the EU on 13 July 2017 for the treatment of nonHodgkin's lymphoma (NHL), granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris (PV). The marketing authorisation was initially valid for a 5-year period.

Ritemvia is a biosimilar medicine of MabThera. There are other biosimilar medicinal products of MabThera authorised and marketed in the EU. MabThera is authorised in the EU to treat non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Ritemvia was a duplicate of Truxima which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for another duplicate, Blitzima.

The European Public Assessment Report (EPAR) for Ritemvia is updated to indicate that the marketing authorisation is no longer valid.

Ritemvia : EPAR - Medicine overview

Reference Number: EMA/413555/2019

English (EN) (745.22 KB - PDF)

**First published:** 15/08/2017

**Last updated:** 16/08/2021

[View](/en/documents/overview/ritemvia-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-275)

български (BG) (827.66 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/bg/documents/overview/ritemvia-epar-medicine-overview_bg.pdf)

español (ES) (733.83 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/es/documents/overview/ritemvia-epar-medicine-overview_es.pdf)

čeština (CS) (811.39 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/cs/documents/overview/ritemvia-epar-medicine-overview_cs.pdf)

dansk (DA) (731.27 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/da/documents/overview/ritemvia-epar-medicine-overview_da.pdf)

Deutsch (DE) (741.31 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/de/documents/overview/ritemvia-epar-medicine-overview_de.pdf)

eesti keel (ET) (720.42 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/et/documents/overview/ritemvia-epar-medicine-overview_et.pdf)

ελληνικά (EL) (856.79 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/el/documents/overview/ritemvia-epar-medicine-overview_el.pdf)

français (FR) (739.57 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fr/documents/overview/ritemvia-epar-medicine-overview_fr.pdf)

hrvatski (HR) (760.19 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hr/documents/overview/ritemvia-epar-medicine-overview_hr.pdf)

italiano (IT) (730.61 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/it/documents/overview/ritemvia-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (749.42 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lv/documents/overview/ritemvia-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (761.2 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lt/documents/overview/ritemvia-epar-medicine-overview_lt.pdf)

magyar (HU) (807.21 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hu/documents/overview/ritemvia-epar-medicine-overview_hu.pdf)

Malti (MT) (811.96 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/mt/documents/overview/ritemvia-epar-medicine-overview_mt.pdf)

Nederlands (NL) (736.69 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/nl/documents/overview/ritemvia-epar-medicine-overview_nl.pdf)

polski (PL) (820.43 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pl/documents/overview/ritemvia-epar-medicine-overview_pl.pdf)

português (PT) (734.79 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pt/documents/overview/ritemvia-epar-medicine-overview_pt.pdf)

română (RO) (761.17 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/ro/documents/overview/ritemvia-epar-medicine-overview_ro.pdf)

slovenčina (SK) (809.31 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sk/documents/overview/ritemvia-epar-medicine-overview_sk.pdf)

slovenščina (SL) (806.03 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sl/documents/overview/ritemvia-epar-medicine-overview_sl.pdf)

Suomi (FI) (730.28 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fi/documents/overview/ritemvia-epar-medicine-overview_fi.pdf)

svenska (SV) (731.06 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sv/documents/overview/ritemvia-epar-medicine-overview_sv.pdf)

## Product information

Ritemvia : EPAR - Product Information

English (EN) (2.76 MB - PDF)

**First published:** 15/08/2017

**Last updated:** 16/08/2021

[View](/en/documents/product-information/ritemvia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-166)

български (BG) (2.52 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/bg/documents/product-information/ritemvia-epar-product-information_bg.pdf)

español (ES) (2.57 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/es/documents/product-information/ritemvia-epar-product-information_es.pdf)

čeština (CS) (3.78 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/cs/documents/product-information/ritemvia-epar-product-information_cs.pdf)

dansk (DA) (2.65 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/da/documents/product-information/ritemvia-epar-product-information_da.pdf)

Deutsch (DE) (2.27 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/de/documents/product-information/ritemvia-epar-product-information_de.pdf)

eesti keel (ET) (2.37 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/et/documents/product-information/ritemvia-epar-product-information_et.pdf)

ελληνικά (EL) (4.44 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/el/documents/product-information/ritemvia-epar-product-information_el.pdf)

français (FR) (3.22 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fr/documents/product-information/ritemvia-epar-product-information_fr.pdf)

hrvatski (HR) (2.53 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hr/documents/product-information/ritemvia-epar-product-information_hr.pdf)

íslenska (IS) (2.93 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/is/documents/product-information/ritemvia-epar-product-information_is.pdf)

italiano (IT) (2.36 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/it/documents/product-information/ritemvia-epar-product-information_it.pdf)

latviešu valoda (LV) (3.79 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lv/documents/product-information/ritemvia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.1 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lt/documents/product-information/ritemvia-epar-product-information_lt.pdf)

magyar (HU) (3.81 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hu/documents/product-information/ritemvia-epar-product-information_hu.pdf)

Malti (MT) (3.99 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/mt/documents/product-information/ritemvia-epar-product-information_mt.pdf)

Nederlands (NL) (2.49 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/nl/documents/product-information/ritemvia-epar-product-information_nl.pdf)

norsk (NO) (2.82 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/no/documents/product-information/ritemvia-epar-product-information_no.pdf)

polski (PL) (3.99 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pl/documents/product-information/ritemvia-epar-product-information_pl.pdf)

português (PT) (2.53 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pt/documents/product-information/ritemvia-epar-product-information_pt.pdf)

română (RO) (2.8 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/ro/documents/product-information/ritemvia-epar-product-information_ro.pdf)

slovenčina (SK) (3.9 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sk/documents/product-information/ritemvia-epar-product-information_sk.pdf)

slovenščina (SL) (3.83 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sl/documents/product-information/ritemvia-epar-product-information_sl.pdf)

Suomi (FI) (2.27 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fi/documents/product-information/ritemvia-epar-product-information_fi.pdf)

svenska (SV) (2.71 MB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sv/documents/product-information/ritemvia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1859/G 09/10/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ritemvia : EPAR - All Authorised presentations

English (EN) (613.89 KB - PDF)

**First published:** 15/08/2017

**Last updated:** 16/08/2021

[View](/en/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-604)

български (BG) (651.55 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/bg/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_bg.pdf)

español (ES) (614.71 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/es/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (670.09 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/cs/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (616.41 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/da/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (615.48 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/de/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (613.38 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/et/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (650.88 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/el/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_el.pdf)

français (FR) (614.6 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fr/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (643.27 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hr/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (615.68 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/is/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (614.31 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/it/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (686.38 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lv/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (642.86 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/lt/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (644.17 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/hu/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (661.98 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/mt/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (614.72 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/nl/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (615.64 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/no/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_no.pdf)

polski (PL) (661.69 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pl/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_pl.pdf)

português (PT) (615.59 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/pt/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_pt.pdf)

română (RO) (644.75 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/ro/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (671.21 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sk/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (655.87 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sl/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (613.61 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/fi/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (614.9 KB - PDF)

**First published:**

15/08/2017

**Last updated:**

16/08/2021

[View](/sv/documents/all-authorised-presentations/ritemvia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ritemvia Active substance rituximab International non-proprietary name (INN) or common name rituximab Therapeutic area (MeSH)

- Lymphoma, Non-Hodgkin
- Microscopic Polyangiitis
- Wegener Granulomatosis

Anatomical therapeutic chemical (ATC) code L01XC02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Ritemvia is indicated in adults for the following indications:

- Non-Hodgkin's lymphoma (NHL) Ritemvia is indicated for the treatment of previously untreated patients with stage III, IV follicular lymphoma in combination with chemotherapy.
- Ritemvia maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
- Ritemvia monotherapy is indicated for treatment of patients with stage III, IV follicular lymphoma who are chemo resistant or are in their second or subsequent relapse after chemotherapy.
- Ritemvia is indicated for the treatment of patients with CD20 positive diffuse large B cell non Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
- Granulomatosis with polyangiitis and microscopic polyangiitis.
- Ritemvia, in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).

## Authorisation details

EMA product number EMEA/H/C/004725

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Opinion adopted 18/05/2017 Marketing authorisation issued 13/07/2017 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ritemvia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (879.23 KB - PDF)

**First published:** 24/10/2017

**Last updated:** 16/08/2021

[View](/en/documents/procedural-steps-after/ritemvia-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ritemvia : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/421799/2017

English (EN) (10.53 MB - PDF)

**First published:** 15/08/2017

**Last updated:** 16/08/2021

[View](/en/documents/assessment-report/ritemvia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ritemvia

Adopted

Reference Number: EMA/CHMP/307703/2017

English (EN) (649.49 KB - PDF)

**First published:** 19/05/2017

**Last updated:** 16/08/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ritemvia_en.pdf)

#### News on Ritemvia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-may-2017) 19/05/2017

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

**This page was last updated on** 16/08/2021

## Share this page

[Back to top](#main-content)